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OUTCOME COMPARISONS OF STEMI AND NSTEMI 
 A 2007 French MI registry study analyzed one-year treatment outcome comparisons of NSTEMI and STEMI patients, where 
treatment decisions were based on provider discretion. STEMI patients were more likely to receive fibrinolytics (28.9 vs. 
0.7%, P<0.0001) and/or PCI (71.0 vs. 51.6%, P<0.0001).15 
 Demographic statistics from a 2010 Polish observational multicentered registry of 13,441 AMI patients: More comorbid 
factors in NSTEMI including median age (68 vs. 63), previous MI (23.9 vs. 14.7%), diabetes (27.6 vs. 22.6%), hypertension 
(70.1 vs. 57.7%) and obesity (20 vs. 17%). Coronary angiography was performed more often in STEMI patients (61.6 vs. 
28.7%), fibrinolytics were administered more often to STEMI patients (8.2 vs. 1%) and two-year mortality rates after 
discharge were lower in STEMI patients (22.9 vs. 26%). Upon discharge, STEMI patients were more likely to receive ACE-
inhibitors (76.2 vs. 74.5%), aspirin (88.6 vs. 84.8%), thienopyridine (63.5 vs. 33.5%), beta-blockers (80.6 vs. 77.4%) and 
statins (82.1 vs. 74%). NSTEMI more likely to have two-year MACE (50.6 vs. 46.7%).18  
 A 2006 study of the CADILLAC trial included 2,082 AMI patients randomized into a 2x2 study where 50% received 
angioplasty with abciximab and 50% received angioplasty alone. Patients with NSTEMI had higher revascularization rates 
(21.8 vs. 11.9%) than STEMI patients. One-year mortality rates were similar (3.4% NSTEMI vs. 4.4% STEMI).5 
 A 2009 retrospective study at the Duke University Medical Center analyzed 4,606 consecutive AMI patients undergoing 
CAG. Early revascularization was achieved more often in STEMI (74.9 vs. 56%) while adjusted hazard ratios remained 
similar between STEMI and NSTEMI (0.73 vs. 0.76, 95% CI).3  
 Long-term outcomes of successful PCI in both STEMI and NSTEMI patients were examined from the PROSPECT (Providing 
Regional Observations to Study Predictors of Events in the Coronary Tree) study. The international multi-centered registry 
study followed 697 post-PCI MI patients for 3-4 years to a primary end point of MACE including death, MI or 
rehospitalization. MACE occurred less frequently in NSTEMI patients than in STEMI patients (19.6 vs. 22.1%).1 
MANAGEMENT OF ACS/MI 
 Aggressive management of AMI may include CAG, percutaneous coronary intervention, coronary artery bypass grafting 
and/or pharmacologic treatment such as anticoagulants, antiplatelets, fibrinolytics and glycoprotein IIb/IIIa antagonists.4 
 Conservative management of AMI includes medical management of anticoagulation, antiplatelet therapy, symptomatic 
treatment and ongoing cardiac enzyme testing.20  
 12-lead ECG is used to determine location of blockage and to differentiate between STEMI and NSTEMI.7 
 12-lead ECG may not clearly differentiate STEMI versus NSTEMI.14  






 43.6% of NSTEMI patients and 27.1% of STEMI patients presented without chest pain and without radiating symptoms 
to the arm, neck or jaw. 2  
 Median delays from initial symptoms to admission shown to be 2.5 hours longer in NSTEMI versus STEMI.15 
DEFINITIVE MANAGEMENT OF STEMI 
 Early CAG with percutaneous coronary intervention (PCI) remains the gold standard for acute management of STEMI, 
provided CAG can be performed within 90-120 minutes of initial ED presentation.8,11 
 CAG indicated even within first 24 hours.17   





 Acute myocardial infarction (AMI) is one of the leading 
causes of death in the United States.  
 The purpose of this study was to examine methods of 
clinical differentiation between ST-segment elevation 
myocardial infarction (STEMI) and non-STEMI (NSTEMI) 
and then to compare the various treatment methods and 
subsequent outcomes in STEMI versus NSTEMI. 
 A compilation of systematic reviews, medical journals, 
practice guidelines, medical texts and meta-analyses were 
researched for the purpose of this study. 
 NSTEMI patients are older, have more comorbidities and 
present with more atypical symptoms than STEMI patients.  
 NSTEMI patients are treated less aggressively than STEMI 
patients both in-hospital and after discharge.  
 Based on current practices, NSTEMI mortality and major 
adverse cardiac events (MACE) rates are higher than in 
STEMI patients. 
 Recent coronary angiography (CAG) outcome comparisons 
generally show similar mortality and hazard ratios and 
suggest better revascularization in NSTEMI than in 
STEMI. 
 Early invasive treatment in NSTEMI has shown more 
positive results than late invasive treatment and is most 
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Abstract 
Introduction 
 AMI is differentiated into ST-segment elevation myocardial 
infarction (STEMI) or non-STEMI (NSTEMI) based on 12-
lead ECG findings.  
 NSTEMI and STEMI management differs, the latter being 
more aggressive. 
Literature Review 
Applicability to Clinical Practice 
Discussion 
 Based on the literature reviewed in this study, STEMI patients currently 
receive more expedient care and more aggressive treatments than NSTEMI 
patients.  
 Provider discretion toward risk assessment and necessity of early invasive 
strategy is required by all of the studied NSTEMI guidelines. The ability of 
providers to differentiate between STEMI and NSTEMI is necessary for proper 
application of treatment guidelines, but many discrepancies are common in 
presentation. 
 According to the literature reviewed in this study, more favorable outcomes are 
observed in STEMI patients based on current practices. However, current 
practices provide more aggressive treatment of STEMI patients than NSTEMI 
patients. The details involved in comparative PCI outcome studies reveal that 
NSTEMI patients have similar outcomes to STEMI patients in early invasive 
therapy strategies.   
 NSTEMI patients may benefit from the more aggressive STEMI strategy. 
 Current NSTEMI practices may require ongoing testing which delay definitive 
treatment from hours to days. This “watchful waiting” approach may be 
contributing to higher mortality and MACE rates in NSTEMI. 
 A more standardized tool may be beneficial to assist in the risk stratification 
component of treatment determination in NSTEMI.    
 Current studies are illustrating statistically that NSTEMI patients are receiving 
favorable results from invasive treatments such as PCI. Some studies show even 
more favorable outcomes than in STEMI patients.  
 With a more vigilant effort to rule out STEMI, management 
of NSTEMI may now be considered a lower priority in an 
acute care setting.  
 Studies are needed to determine if this prioritization is an 
appropriate approach to AMI management and if NSTEMI 
patients have less favorable outcomes as a result. 
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Statement of the Problem 
12-lead ECG study 9 
 
AMI cannot be ruled out  
in any of these examples 
Research Questions 
1. In patients with acute myocardial infarction, is there a 
notable difference in approach to treatments and timeliness of 
care between STEMI and NSTEMI? 
 
2. In patients with acute myocardial infarction, is there a 
notable difference in treatment outcomes of STEMI versus 
NSTEMI? 
Basic 12-lead ECD interpretation 6 
The 12-lead ECG illustrating potential 
posterior ST-elevation myocardial 
infarction as evidenced by ST-depression 
and dominant R-wave in leads V1-V2, in 
the context of chest pain, which doctors 
and paramedics were asked to interpret. 14 
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 NSTEMI patients may be monitored by repeating cardiac enzymes, 12-lead 
ECG’s and assessment of symptoms at intervals of four to six hours.4  
 The Advanced Cardiovascular Life Support® (ACLS) ACS algorithm 
differentiates patients without ST-segment elevation into high risk and 
low/intermediate risk.20 
 Invasive strategy (CAG) shown to be effective in reducing the incidence of 
myocardial infarction within six to twelve months (RR 0.73, 95% CI 0.62 to 
0.86) and three to five years (RR 0.78, 95% CI 0.67 to 0.92). This study 
included 7,818 chest pain patients from 5 prospective randomized controlled 
trials.12 
 Current NSTEMI guidelines require provider discretion for risk stratification 
and determination of invasive or conservative strategies.13,16  Acute Coronary Syndromes Algorithm - American Heart Association 20 
